(NASDAQ: FTRE) Fortrea Holdings's forecast annual revenue growth rate of 2.69% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.56%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.83%.
Fortrea Holdings's revenue in 2026 is $2,676,500,000.On average, 14 Wall Street analysts forecast FTRE's revenue for 2026 to be $256,960,200,000, with the lowest FTRE revenue forecast at $242,409,900,000, and the highest FTRE revenue forecast at $267,135,900,000. On average, 14 Wall Street analysts forecast FTRE's revenue for 2027 to be $264,948,600,000, with the lowest FTRE revenue forecast at $246,974,700,000, and the highest FTRE revenue forecast at $279,023,400,000.
In 2028, FTRE is forecast to generate $276,265,500,000 in revenue, with the lowest revenue forecast at $257,911,200,000 and the highest revenue forecast at $291,006,000,000.